CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers
Article in Aging (January 2024)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
The roles, molecular interactions, and therapeutic value of CDK16 in human cancers
Article in Biomedicine & Pharmacotherapy (May 2023)
Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis
Article in Frontiers in Oncology (March 2023)